Matching articles for "Saxenda"
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • August 5, 2024; (Issue 1708)
...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Tirzepatide (Zepbound) for Chronic Weight Management
The Medical Letter on Drugs and Therapeutics • December 25, 2023; (Issue 1692)
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide, which was approved by
the FDA as Mounjaro for treatment of type 2 diabetes
in...
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide, which was approved by
the FDA as Mounjaro for treatment of type 2 diabetes
in 2022, has now been approved as Zepbound (Lilly)
for chronic weight management in adults who have
a BMI ≥30 kg/m2 or a BMI ≥27 kg/m2 and at least
one weight-related comorbidity. The injectable
GLP-1 receptor agonists liraglutide (Saxenda) and
semaglutide (Wegovy) are approved for chronic
weight management in patients ≥12 years old.
In Brief: GI Effects of GLP-1 Receptor Agonists
The Medical Letter on Drugs and Therapeutics • November 27, 2023; (Issue 1690)
Glucagon-like peptide-1 (GLP-1) receptor agonists and
the dual glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2...
Glucagon-like peptide-1 (GLP-1) receptor agonists and
the dual glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes
and weight management (see Table 1), but they delay
gastric emptying and commonly cause nausea and
vomiting. Gastroparesis and bowel obstruction (ileus)
have also been reported with their use.
In Brief: Semaglutide (Wegovy) for Weight Loss in Children
The Medical Letter on Drugs and Therapeutics • February 20, 2023; (Issue 1670)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy), which was
approved by the FDA in 2021 for chronic weight
management in adults, has now been approved for
chronic weight...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide (Wegovy), which was
approved by the FDA in 2021 for chronic weight
management in adults, has now been approved for
chronic weight management in children ≥12 years old
with an initial BMI in the ≥95th percentile for age and
sex.Semaglutide is also available as Ozempic and
Rybelsus for treatment of type 2 diabetes in adults.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 14, 2022; (Issue 1663)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • July 11, 2022; (Issue 1654)
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022; (Issue 1651)
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight loss.
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • May 30, 2022; (Issue 1651)
...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Semaglutide (Wegovy) for Weight Loss
The Medical Letter on Drugs and Therapeutics • July 12, 2021; (Issue 1628)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide, previously approved
by the FDA as Ozempic to treat type 2 diabetes and
to reduce the risk of major adverse cardiovascular
events in adults with type 2 diabetes and established
cardiovascular disease, has now been approved in
a higher dose as Wegovy (Novo Nordisk) for chronic
weight management in adults with or without type 2
diabetes who have a body mass index (BMI) ≥30 kg/m2
or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity
(e.g., hypertension, dyslipidemia). An oral formulation
of semaglutide (Rybelsus) has been available since
2019 for treatment of type 2 diabetes, but it is not
approved for weight management. Liraglutide
(Saxenda), another subcutaneously injected GLP-1
receptor agonist, was approved for chronic weight
management in 2015.
Semaglutide (Ozempic) for Weight Loss
The Medical Letter on Drugs and Therapeutics • April 5, 2021; (Issue 1621)
In recently published clinical trials, once-weekly
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment...
In recently published clinical trials, once-weekly
subcutaneous injection of the glucagon-like peptide 1
(GLP-1) receptor agonist semaglutide (Ozempic – Novo Nordisk), which is FDA-approved for treatment of
type 2 diabetes and to reduce the risk of major adverse
cardiovascular events in adults with type 2 diabetes
and established cardiovascular disease, has reduced
body weight significantly in patients with and without
type 2 diabetes when given in addition to lifestyle
intervention. Liraglutide (Saxenda), another GLP-1
receptor agonist, has been FDA-approved for chronic
weight management since 2015.
Diet, Drugs, Devices, and Surgery for Weight Management
The Medical Letter on Drugs and Therapeutics • June 4, 2018; (Issue 1548)
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs are FDA-approved
for weight reduction and maintenance (see
Table 1), and procedures such as endoscopic
placement of dilated balloons have produced beneficial
short-term results (see Table 2), but bariatric
surgery has been the most effective intervention for
sustainable long-term weight loss and reduction of
obesity-related comorbidities.
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • June 4, 2018; (Issue 1548)
...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Liraglutide (Saxenda) for Weight Loss
The Medical Letter on Drugs and Therapeutics • June 22, 2015; (Issue 1471)
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as...
The injectable glucagon-like peptide-1 (GLP-1)
receptor agonist liraglutide, previously approved by the
FDA for treatment of type 2 diabetes as Victoza, has
now also been approved at a higher dose as Saxenda
(Novo Nordisk) for chronic weight management
in adults with a BMI ≥30, or a BMI ≥27 with a
weight-related comorbidity such as hypertension,
dyslipidemia, or diabetes.
Diet, Drugs, and Surgery for Weight Loss
The Medical Letter on Drugs and Therapeutics • February 16, 2015; (Issue 1462)
Adults with a body mass index (BMI) between
25 and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. Losing even
a small amount of weight and increasing physical
activity...
Adults with a body mass index (BMI) between
25 and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. Losing even
a small amount of weight and increasing physical
activity can prevent some of the complications
of obesity, particularly type 2 diabetes. Diet and
exercise are the preferred methods for losing weight,
but long-term failure rates are high. Several drugs
have been approved by the FDA for weight reduction,
but adherence is poor, adverse effects are common,
and patients usually regain the lost weight when
the drug is stopped. Bariatric surgery can produce
substantial weight loss and significantly reduce
obesity-related comorbidities; long-term data on its
safety are encouraging, but still limited. Guidelines
for the management of overweight or obese adults
have recently been published.
Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
The Medical Letter on Drugs and Therapeutics • November 10, 2014; (Issue 1455)
The FDA has approved a fixed-dose combination of
the opioid receptor antagonist naltrexone (ReVia, and
others) and the antidepressant and smoking cessation
agent bupropion (Wellbutrin SR, Zyban, and...
The FDA has approved a fixed-dose combination of
the opioid receptor antagonist naltrexone (ReVia, and
others) and the antidepressant and smoking cessation
agent bupropion (Wellbutrin SR, Zyban, and others),
as Contrave (Orexigen/Takeda) for weight loss. The
combination was approved for use as an adjunct to
diet and increased physical activity in patients with a
body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2
and one or more weight-related comorbidities such as
hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled substance.